FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
You may also be interested in...
The US Senate on a 72-18 vote approved radiation oncologist Stephen Hahn as Commissioner of the FDA on 12 December. Voting “no” were a block of liberal Democrats, including the ranking member of a key Senate health committee. Industry advocates and most senators said Hahn is an excellent choice to lead the FDA, but some fear he will not move quickly enough to ban candy flavors in vaping products favored by teens.
Hahn Fields Queries On Electrical Stim Devices, Molybdenum Supplies For Imaging At FDA Confirmation Hearing
MD Anderson Cancer Center chief medical officer Stephen Hahn fielded a number of questions senators asked at his 20 November confirmation hearing to lead the US FDA. Chief among them were inquiries about his government experience level, whether he would expedite a ban on electrical stimulation devices used against the intellectually disabled, and how he would address a shortage of molybdenum-99 used in advanced imaging scans.
US Democratic Sens. Elizabeth Warren of Massachusetts and Patty Murray of Washington State recently sent a letter to FDA officials Brett Giroir and Jeff Shuren that raises doubts about a planned bill calling for a progressive approval pathway for medical devices.